Worldwide Healthcare Trust PLC - Half-year Report PR Newswire LONDON, United Kingdom, November 15 LONDON STOCK EXCHANGE ANNOUNCEMENTWorldwide Healthcare Trust PLCUnaudited ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

For years, drug de­vel­op­ers work­ing to treat an ad­vanced form of fat­ty liv­er dis­ease known as MASH were chas­ing wide-open ter­rain. There were no prod­ucts … ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semaglutide.

Compounded GLP-1s for Weight Loss: What Are They and Are They Safe? GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...

a different target than the GLP-1 agonist drugs dominating the obesity market today. The drug completed a phase 1 trial with 124 patients in August, meant in part to assess whether BI 1820237 ...

HT-6184, a first-in-class, selective, and orally bioavailable inhibitor of the NEK7/NLRP3 inflammasome, is undergoing preclinical evaluation in combination with the GLP-1 agonist semaglutide.

The Dallas-headquartered chain with more than 1,300 stores across five continents has announced a new GLP-1 Support Menu ... designed for people using GLP-1 agonists, a class of medication used ...

Smoothie King launched a GLP-1 Support Menu for guests using GLP-1 agonists to help them achieve their weight loss or weight management goals. This dedicated menu will be available online, within the ...

The family of weight-loss jabs known as GLP-1 agonists are among pharma’s biggest blockbusters. But drugs like Ozempic have the potential to do much more than tackle diabetes and obesity.

"Year to date" sales for 2021, 2022, 2023, and 2024 sales are shown in series at the top of the table and then just below a comparison of 2024 versus 2023 and 2024 versus 2022 is displayed.